| Literature DB >> 29562508 |
Hélène Courtemanche1, Edith Bigot2, Matthieu Pichelin3,4,5, Béatrice Guyomarch4, Claire Boutoleau-Bretonnière1, Cédric Le May5, Pascal Derkinderen1, Bertrand Cariou3,4,5.
Abstract
The role of PCSK9 in Alzheimer's disease (AD) is controversial. We compared cerebrospinal fluid (CSF) PCSK9 concentrations in 36 AD and 31 non-AD patients. CSF PCSK9 levels did not differ between AD and non-AD groups (2.80 versus 2.62 ng/mL). However, PCSK9 CSF levels were increased in AD and non-AD patients with other neurodegenerative process (non-AD ND, n = 20) compared to patients without neurodegenerative disorders (non-ND, n = 11): 2.80 versus 2.30 (p < 0.005) and 2.83 versus 2.30 ng/mL (p = NS), respectively. CSF PCSK9 were positively correlated with AD biomarkers (Aβ1-42, T-tau, and P-tau). PCSK9 concentrations in CSF are increased in neurodegenerative disorders rather than specifically in AD.Entities:
Keywords: Aβ1-42; LDL-cholesterol; P-tau; PCSK9; T-tau; cerebrospinal fluid; frontotemporal lobar degeneration
Mesh：
Substances：
Year: 2018 PMID： 29562508 DOI： 10.3233/JAD-170993
Source DB: PubMed Journal: J Alzheimers Dis ISSN： 1387-2877 Impact factor: 4.472